Share on StockTwits

Protalix BioTherapeutics (NYSE:PLX) posted its quarterly earnings results on Friday. The company reported ($0.07) earnings per share for the quarter, meeting the analysts’ consensus estimate of ($0.07), AnalystRatingsNetwork.com reports.

Shares of Protalix BioTherapeutics (NYSE:PLX) opened at 2.72 on Friday. Protalix BioTherapeutics has a 1-year low of $2.45 and a 1-year high of $5.60. The stock has a 50-day moving average of $3.29 and a 200-day moving average of $4.08. The company’s market cap is $252.5 million.

On the ratings front, analysts at Jefferies Group reiterated a “hold” rating on shares of Protalix BioTherapeutics in a research note on Monday. They now have a $3.50 price target on the stock, down previously from $4.25.

Protalix BioTherapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.